Granted Patent
B2
US 12,735,503 · App. 18/547,663 · Granted Sep 15, 2026
Anti-MUC1-C antibodies and CAR-T structures
Inventors:
Katherine Harris (Thousand Oaks, CA); Brian Avanzino (Thousand Oaks, CA); Nathan Trinklein (Thousand Oaks, CA); Karen Chang (Thousand Oaks, CA); Nicole Allen (Thousand Oaks, CA)
Assignee:
TeneoBio, Inc.
C07K16/3092A61K40/11A61K40/31A61K40/4257A61P35/00C07K14/7051C12N5/0636A61K2239/31A61K2239/38A61K2239/49A61K2239/59C07K2317/569C07K2317/92C07K2319/33C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Anti-MUC1-C antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of MUC1-C.
Claims (17)
1 . An isolated antibody that binds to MUC1-C, comprising a heavy chain variable region comprising:
(a) a CDR1 sequence of SEQ ID NO: 1, a CDR2 sequence of SEQ ID NO: 2, and a CDR3 sequence of SEQ ID NO: 3; or
(b) a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 5, and a CDR3 sequence of SEQ ID NO: 6.
2 . A CAR-T cell comprising a CAR comprising an extracellular antigen-binding domain that binds to MUC1-C, comprising a heavy chain variable region comprising:
(a) a CDR1 sequence of SEQ ID NO: 1, a CDR2 sequence of SEQ ID NO: 2, and a CDR3 sequence of SEQ ID NO: 3; or
(b) a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 5, and a CDR3 sequence of SEQ ID NO: 6.
3 . The CAR-T cell of claim 2 , wherein the CDR1, CDR2 and CDR3 sequences are present in a human VH framework.
4 . The CAR-T cell of claim 2 , wherein the heavy chain variable region comprises a CDR1 sequence of SEQ ID NO: 1, a CDR2 sequence of SEQ ID NO: 2, and a CDR3 sequence of SEQ ID NO: 3.
5 . The CAR-T cell of claim 2 , wherein the heavy chain variable region comprises a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 5, and a CDR3 sequence of SEQ ID NO: 6.
6 . The CAR-T cell of claim 2 , wherein the extracellular antigen-binding domain that binds to MUC1-C comprises a heavy chain variable region having at least 95% sequence identity to SEQ ID NO: 7 or SEQ ID NO: 8.
7 . The CAR-T cell of claim 6 , wherein the extracellular antigen-binding domain that binds to MUC1-C comprises a heavy chain variable region sequence selected from the group consisting of: SEQ ID NOs: 7 and 8.
8 . The CAR-T cell of claim 7 , wherein the extracellular antigen-binding domain that binds to MUC1-C comprises the heavy chain variable region sequence of SEQ ID NO: 7.
9 . The CAR-T cell of claim 7 , wherein the extracellular antigen-binding domain that binds to MUC1-C comprises the heavy chain variable region sequence of SEQ ID NO: 8.
10 . A pharmaceutical composition comprising the CAR-T cell of claim 2 .
11 . A kit comprising the CAR-T cell of claim 2 and instructions for use.
12 . The kit of claim 11 , further comprising at least one additional reagent.
13 . The kit of claim 12 , wherein the at least one additional reagent comprises a chemotherapeutic drug.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2024
From: HARRIS, KATHERINE; AVANZINO, BRIAN; TRINKLEIN, NATHAN; CHANG, KAREN; ALLEN, NICOLE
To: TENEOBIO, INC.
Reel/Frame 066757/0346 →
Continuity (2)
Provisional Application
63154618
· Feb 26, 2021
References Cited (400)
US 4275149A
· Litman et al.
· 1981
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5500360A
· Ahlquist et al.
· 1996
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5585097A
· Bolt et al.
· 1996
[cited by applicant]
US 5595097A
· Anderson
· 1997
[cited by applicant]
US 5693761A
· Queen et al.
· 1997
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 5877299A
· Thomas et al.
· 1999
[cited by applicant]
US 5929212A
· Jolliffe et al.
· 1999
[cited by applicant]
US 5968509A
· Gorman et al.
· 1999
[cited by applicant]
US 6037453A
· Jardieu et al.
· 2000
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 6548640B1
· Winter
· 2003
[cited by applicant]
US 6706265B1
· Bolt et al.
· 2004
[cited by applicant]
US 6750325B1
· Jolliffe et al.
· 2004
[cited by applicant]
US 6982321B2
· Winter
· 2006
[cited by applicant]
US 7083785B2
· Browning et al.
· 2006
[cited by applicant]
US 7262276B2
· Huang et al.
· 2007
[cited by applicant]
US 7381803B1
· Weiner et al.
· 2008
[cited by applicant]
US 7541513B2
· Bruggeman et al.
· 2009
[cited by applicant]
US 7635472B2
· Kufer et al.
· 2009
[cited by applicant]
US 7691804B2
· Jeffrey et al.
· 2010
[cited by applicant]
US 7728114B2
· Mach et al.
· 2010
[cited by applicant]
US 7862813B2
· Bjork, Jr.
· 2011
[cited by applicant]
US 8236308B2
· Kischel et al.
· 2012
[cited by applicant]
US 8367888B2
· Brüggemann et al.
· 2013
[cited by applicant]
US 8703485B2
· Buelow
· 2014
[cited by applicant]
US 8883150B2
· Craig et al.
· 2014
[cited by applicant]
US 9034324B2
· Kalled et al.
· 2015
[cited by applicant]
US 9150664B2
· Kufer et al.
· 2015
[cited by applicant]
US 9340621B2
· Kufer et al.
· 2016
[cited by applicant]
US 9365655B2
· Craig et al.
· 2016
[cited by applicant]
US 9598500B2
· Kufer et al.
· 2017
[cited by applicant]
US 9650430B2
· Browning et al.
· 2017
[cited by applicant]
US 9657102B2
· Smith et al.
· 2017
[cited by applicant]
US 20010024811A1
· Khosla et al.
· 2001
[cited by applicant]
US 20010024812A1
· Guegler et al.
· 2001
[cited by applicant]
US 20020066516A1
· Cornell
· 2002
[cited by applicant]
US 20040110226A1
· Lazar et al.
· 2004
[cited by applicant]
US 20060008548A1
· Tung
· 2006
[cited by applicant]
US 20070065437A1
· Elson et al.
· 2007
[cited by applicant]
US 20100122358A1
· Brüggemann et al.
· 2010
[cited by applicant]
US 20100150918A1
· Kufer et al.
· 2010
[cited by applicant]
US 20110129458A1
· Dolk et al.
· 2011
[cited by applicant]
US 20130129729A1
· Kischel et al.
· 2013
[cited by applicant]
US 20130195888A1
· Wang et al.
· 2013
[cited by applicant]
US 20130273055A1
· Borges et al.
· 2013
[cited by applicant]
US 20140056897A1
· Buelow et al.
· 2014
[cited by applicant]
US 20140308285A1
· Yan et al.
· 2014
[cited by applicant]
US 20150118251A1
· Deslandes et al.
· 2015
[cited by applicant]
US 20160355591A1
· Goldenberg et al.
· 2016
[cited by applicant]
US 20190284294A1
· Deslandes et al.
· 2019
[cited by applicant]
US 20190328784A1
· Ostertag et al.
· 2019
[cited by applicant]
US 20200085839A1
· Sidransky et al.
· 2020
[cited by applicant]
US 20200095305A1
· Browning et al.
· 2020
[cited by applicant]
US 20200095319A1
· Kufer et al.
· 2020
[cited by applicant]
US 20200138865A1
· Kochenderfer et al.
· 2020
[cited by applicant]
US 20200181228A1
· Bachmann et al.
· 2020
[cited by applicant]
US 20200339685A1
· Schellenberger et al.
· 2020
[cited by applicant]
US 20210047407A1
· Christian et al.
· 2021
[cited by applicant]
US 20210139577A1
· Dillon et al.
· 2021
[cited by applicant]
US 20210139584A1
· Minella et al.
· 2021
[cited by applicant]
US 20210163620A1
· Granda et al.
· 2021
[cited by applicant]
US 20210284732A1
· Zugmaier et al.
· 2021
[cited by applicant]
US 20210341487A1
· Partridge et al.
· 2021
[cited by applicant]
US 20210355215A1
· Jorgensen et al.
· 2021
[cited by applicant]
US 20210388106A1
· Van Schooten et al.
· 2021
[cited by applicant]
US 20210403587A1
· Buelow et al.
· 2021
[cited by applicant]
US 20220098324A1
· Weiner et al.
· 2022
[cited by applicant]
US 20220144947A1
· Smith et al.
· 2022
[cited by applicant]
US 20220251243A1
· Kufer et al.
· 2022
[cited by applicant]
US 20220259547A1
· Khurshid
· 2022
[cited by applicant]
US 20220306741A1
· Sharma et al.
· 2022
[cited by applicant]
US 20220332820A1
· Harris et al.
· 2022
[cited by applicant]
US 20220378908A1
· Zhu et al.
· 2022
[cited by applicant]
US 20220389055A1
· Davis et al.
· 2022
[cited by applicant]
US 20220396599A1
· Wang et al.
· 2022
[cited by applicant]
US 20220403035A1
· Anlahr et al.
· 2022
[cited by applicant]
US 20230057602A1
· Burgess et al.
· 2023
[cited by applicant]
US 20230060847A1
· Trinklein et al.
· 2023
[cited by applicant]
US 20230082151A1
· Trinklein et al.
· 2023
[cited by applicant]
US 20230242668A1
· Van Schooten et al.
· 2023
[cited by applicant]
US 20230257473A1
· Trinklein et al.
· 2023
[cited by applicant]
US 20230272075A1
· Trinklein et al.
· 2023
[cited by applicant]
CA 2828347A1
· 2012
[cited by applicant]
CN 1551886A
· 2004
[cited by applicant]
CN 1889979A
· 2007
[cited by applicant]
CN 101627055A
· 2010
[cited by applicant]
CN 102119174A
· 2011
[cited by applicant]
CN 1889979B
· 2012
[cited by applicant]
CN 103619876A
· 2014
[cited by applicant]
CN 104877026A
· 2015
[cited by applicant]
CN 104968682A
· 2015
[cited by applicant]
CN 105143263A
· 2015
[cited by applicant]
CN 105384825A
· 2016
[cited by applicant]
CN 105777906A
· 2016
[cited by applicant]
CN 105968203A
· 2016
[cited by applicant]
CN 105968204A
· 2016
[cited by applicant]
CN 106029098A
· 2016
[cited by applicant]
CN 105384825B
· 2018
[cited by applicant]
CN 108473589A
· 2018
[cited by applicant]
CN 101874042B
· 2018
[cited by applicant]
CN 103703024B
· 2018
[cited by applicant]
CN 104114578B
· 2018
[cited by applicant]
CN 101874042B9
· 2019
[cited by applicant]
CN 104877026B
· 2019
[cited by applicant]
CN 111683966A
· 2020
[cited by applicant]
CN 112351997A
· 2021
[cited by applicant]
CN 112521513A
· 2021
[cited by applicant]
CN 104710528B
· 2023
[cited by applicant]
EP 2762496A1
· 2014
[cited by applicant]
EP 2762497A1
· 2014
[cited by applicant]
EP 1210425B2
· 2015
[cited by applicant]
EP 2970472A1
· 2016
[cited by applicant]
EP 2780374B1
· 2019
[cited by applicant]
EP 2780375B1
· 2019
[cited by applicant]
EP 3611193A1
· 2020
[cited by applicant]
EP 3623385A1
· 2020
[cited by applicant]
EP 3819007A1
· 2021
[cited by applicant]
EP 3830122A1
· 2021
[cited by applicant]
EP 3912997A2
· 2021
[cited by applicant]
EP 3411402B1
· 2021
[cited by applicant]
EP 3974453A2
· 2022
[cited by applicant]
EP 4039709A1
· 2022
[cited by applicant]
EP 4058148A1
· 2022
[cited by applicant]
EP 4171750A1
· 2023
[cited by applicant]
JP 2012504403A
· 2012
[cited by applicant]
JP 2012521211A5
· 2013
[cited by applicant]
JP 2013528569A
· 2013
[cited by applicant]
JP 2014500879A
· 2014
[cited by applicant]
JP 2014515598A
· 2014
[cited by applicant]
JP 2014520088A
· 2014
[cited by applicant]
JP 2015521032A
· 2015
[cited by applicant]
JP 5836927B2
· 2015
[cited by applicant]
JP 2015535002A
· 2015
[cited by applicant]
JP 2016500256A
· 2016
[cited by applicant]
JP 2016538275A
· 2016
[cited by applicant]
JP 2019528044A
· 2019
[cited by applicant]
JP 6923292B2
· 2021
[cited by applicant]
JP 7030109B2
· 2022
[cited by applicant]
RU 2492186C2
· 2013
[cited by applicant]
RU 2561457C2
· 2015
[cited by applicant]
RU 2014147452A
· 2016
[cited by applicant]
WO WO1996027011A1
· 1996
[cited by applicant]
WO WO1996032478A1
· 1996
[cited by applicant]
WO WO1997034631A1
· 1997
[cited by applicant]
WO WO1998050431A2
· 1998
[cited by applicant]
WO WO2000040716A2
· 2000
[cited by applicant]
WO WO2001012812A2
· 2001
[cited by applicant]
WO WO2001024811A1
· 2001
[cited by applicant]
WO WO2001024812A1
· 2001
[cited by applicant]
WO WO2001077342A1
· 2001
[cited by applicant]
WO WO2001087977A2
· 2001
[cited by applicant]
WO WO2002066516A2
· 2002
[cited by applicant]
WO WO2004106383A1
· 2004
[cited by applicant]
WO WO2005040220A1
· 2005
[cited by applicant]
WO WO2005058815A2
· 2005
[cited by applicant]
WO WO2005061547A2
· 2005
[cited by applicant]
WO WO2006008548A2
· 2006
[cited by applicant]
WO WO2006089232A2
· 2006
[cited by applicant]
WO WO2007042261A2
· 2007
[cited by applicant]
WO WO2007042289A2
· 2007
[cited by applicant]
WO WO2007055916A2
· 2007
[cited by applicant]
WO WO2007066109A1
· 2007
[cited by applicant]
WO WO2007117505A2
· 2007
[cited by applicant]
WO WO2007117600A2
· 2007
[cited by applicant]
WO WO2008119565A2
· 2008
[cited by applicant]
WO WO2008119566A2
· 2008
[cited by applicant]
WO WO2008119567A2
· 2008
[cited by applicant]
WO WO2008151081A1
· 2008
[cited by applicant]
WO WO2009041643A1
· 2009
[cited by applicant]
WO WO2009055669A2
· 2009
[cited by applicant]
WO WO2009132058A2
· 2009
[cited by applicant]
WO WO2010007082A1
· 2010
[cited by applicant]
WO WO2010032061A1
· 2010
[cited by applicant]
WO WO2010037835A2
· 2010
[cited by applicant]
WO WO2010037836A2
· 2010
[cited by applicant]
WO WO2010037837A2
· 2010
[cited by applicant]
WO WO2010037838A2
· 2010
[cited by applicant]
WO WO2010104949A2
· 2010
[cited by applicant]
WO WO2010109165A2
· 2010
[cited by applicant]
WO WO2011069104A2
· 2011
[cited by applicant]
WO WO2011097603A1
· 2011
[cited by applicant]
WO WO2011121110A1
· 2011
[cited by applicant]
WO WO2012066058A1
· 2012
[cited by applicant]
WO WO2012122512A1
· 2012
[cited by applicant]
WO WO2012122528A1
· 2012
[cited by applicant]
WO WO2012143498A1
· 2012
[cited by applicant]
WO WO2012145714A2
· 2012
[cited by applicant]
WO WO2012162067A2
· 2012
[cited by applicant]
WO WO2012163805A1
· 2012
[cited by applicant]
WO WO2013022091A1
· 2013
[cited by applicant]
WO WO2013072406A1
· 2013
[cited by applicant]
WO WO2013072415A1
· 2013
[cited by applicant]
WO WO2013154760A1
· 2013
[cited by applicant]
WO WO2013158856A2
· 2013
[cited by applicant]
WO WO2014022540A1
· 2014
[cited by applicant]
WO WO2014047231A1
· 2014
[cited by applicant]
WO WO2014068079A1
· 2014
[cited by applicant]
WO WO2014089335A2
· 2014
[cited by applicant]
WO WO2014093908A2
· 2014
[cited by applicant]
WO WO2014112144A1
· 2014
[cited by applicant]
WO WO2014122143A1
· 2014
[cited by applicant]
WO WO2014122144A1
· 2014
[cited by applicant]
WO WO2014140248A1
· 2014
[cited by applicant]
WO WO2014141192A1
· 2014
[cited by applicant]
WO WO2014144722A2
· 2014
[cited by applicant]
WO WO2015063339A1
· 2015
[cited by applicant]
WO WO2015095412A1
· 2015
[cited by applicant]
WO WO2015116753A1
· 2015
[cited by applicant]
WO WO2015121383A1
· 2015
[cited by applicant]
WO WO2015130416A1
· 2015
[cited by applicant]
WO WO2015149077A1
· 2015
[cited by applicant]
WO WO2016014789A2
· 2016
[cited by applicant]
WO WO2016014974A2
· 2016
[cited by applicant]
WO WO2016030414A1
· 2016
[cited by applicant]
WO WO2016062990A1
· 2016
[cited by applicant]
WO WO2016079050A1
· 2016
[cited by applicant]
WO WO2016079076A1
· 2016
[cited by applicant]
WO WO2016079081A1
· 2016
[cited by applicant]
WO WO2016079177A1
· 2016
[cited by applicant]
WO WO2016094304A2
· 2016
[cited by applicant]
WO WO2016113555A1
· 2016
[cited by applicant]
WO WO2016124670A1
· 2016
[cited by applicant]
WO WO2016128487A1
· 2016
[cited by applicant]
WO WO2016187546A1
· 2016
[cited by applicant]
WO WO2016187594A1
· 2016
[cited by applicant]
WO WO2017023761A1
· 2017
[cited by applicant]
WO WO2017025038A1
· 2017
[cited by applicant]
WO WO2017031104A1
· 2017
[cited by applicant]
WO WO2017053856A1
· 2017
[cited by applicant]
WO WO2017081211A2
· 2017
[cited by applicant]
WO WO2017122018A1
· 2017
[cited by applicant]
WO WO2017122019A1
· 2017
[cited by applicant]
WO WO2017134134A1
· 2017
[cited by applicant]
WO WO2017223111A1
· 2017
[cited by applicant]
WO WO2018039180A1
· 2018
[cited by applicant]
WO WO2018052503A1
· 2018
[cited by applicant]
WO WO2018083204A1
· 2018
[cited by applicant]
WO WO2018114795A1
· 2018
[cited by applicant]
WO WO2018119215A1
· 2018
[cited by applicant]
WO WO2018237006A1
· 2018
[cited by applicant]
WO WO2018237037A2
· 2018
[cited by applicant]
WO WO2019000223A1
· 2019
[cited by applicant]
WO WO2019006072A1
· 2019
[cited by applicant]
WO WO2019012260A1
· 2019
[cited by applicant]
WO WO2019055689A1
· 2019
[cited by applicant]
WO WO2019075413A1
· 2019
[cited by applicant]
WO WO2019126724A1
· 2019
[cited by applicant]
WO WO2019126756A1
· 2019
[cited by applicant]
WO WO2019133761A1
· 2019
[cited by applicant]
WO WO2019177854A1
· 2019
[cited by applicant]
WO WO2020018922A1
· 2020
[cited by applicant]
WO WO2020025596A1
· 2020
[cited by applicant]
WO WO2020061478A2
· 2020
[cited by applicant]
WO WO2020087065A1
· 2020
[cited by applicant]
WO WO2020206330A1
· 2020
[cited by applicant]
WO WO2020252366A1
· 2020
[cited by applicant]
WO WO2021094000A1
· 2021
[cited by applicant]
WO WO2021127489A1
· 2021
[cited by applicant]
WO WO2021127505A1
· 2021
[cited by applicant]
WO WO2021222578A1
· 2021
[cited by applicant]
WO WO2021222616A1
· 2021
[cited by applicant]
WO WO2021228783A1
· 2021
[cited by applicant]
WO WO2022006316A1
· 2022
[cited by applicant]
WO WO2022103781A1
· 2022
[cited by applicant]
WO WO2022109010A1
· 2022
[cited by applicant]
WO WO2022183074A2
· 2022
[cited by applicant]
WO WO2022183101A1
· 2022
[cited by applicant]
WO WO2022212848A1
· 2022
[cited by applicant]
WO WO2022216864A1
· 2022
[cited by applicant]
WO WO2022221698A1
· 2022
[cited by applicant]
WO WO2022271987A1
· 2022
[cited by applicant]
WO WO2023004197A1
· 2023
[cited by applicant]
“A Global Search Engine for Antibodies (A Search for “#sc-57037” in the Antibody Directory, the Details for “#sc-57037” in the Antibody Directory, and A Search for “#sc-57037” in the Antibody Registry),” cited on Feb. 2…
[cited by applicant]
A Report of an Epitope-exchange Study on the Binding of Vicky-1 to BCMA Epitope Cluster 3, Cited on Feb. 24, 2023, In the EP Opposition for EP2780375, 6 Pages.
[cited by applicant]
Aalberse R.C., et al., “IgG4 Breaking the Rules,” Immunology, 2002, vol. 105, pp. 9-19.
[cited by applicant]
Abcam: “Product datasheet, Anti-BCMA antibody [Vicky-1] ab17323,” cited on Sep. 9, 2022 in the EP Opposition for EP2780375, 3 Pages.
[cited by applicant]
Adams G.P., et al., “Prolonged in Vivo Tumour Retention of a Human Diabody Targeting the Extracellular Domain of Human HER2/neu,” British Journal of Cancer, 1998, vol. 77, No. 9, pp. 1405-1412.
[cited by applicant]
Alanine-Scanning Report, In the EP Opposition for EP2780375, Cited on Feb. 23, 2023, 9 Pages.
[cited by applicant]
Alderson R.F., et al., “CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies,” Clinical Cancer Research, Feb. 1, 2009, vol. 15, No. 3, pp. 832-839.
[cited by applicant]
Aldred S.F., “Winning the Numbers Game: Novel Multi-specific Therapeutics from a Diverse Collection of Human Domain Antibodies,” Teneobio, 2016, pp. 1-16, [Retrieved on Oct. 10, 2016] Retrieved from URL: https://2019.la…
[cited by applicant]
Alexaki V-I., et al., “Adipocytes as Immune Cells: Differential Expression of Tweak, BAFF, and April and their Receptors (Fn14, BAFF-R, TACI and BCMA) at Different Stages of Normal and Pathological Adipose Tissue Develo…
[cited by applicant]
Ali S.A., et al., “T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor cause Remissions of Multiple Myeloma,” Blood, Sep. 29, 2016, vol. 128, No. 13, pp. 1688-1700.
[cited by applicant]
Almagro J.C., et al., “Identification of Differences in the Specificity-determining Residues of Antibodies That Recognize Antigens of Different Size: Implications for the Rational Design of Antibody Repertoires,” Journa…
[cited by applicant]
Amiri S.A., et al., “A Novel Anti-CD22 scFV-apoptin Fusion Protein Induces Apoptosis in Malignant B-cells,” AMB Express, Dec. 2017, vol. 7, No. 1: 112, 11 Pages, ISSN 0004931985.
[cited by applicant]
Anonymous, “Antibody Therapeutics—Teneobio's Next Generation of Multispecific Antibody Therapeutics,” Drug Development and Delivery, Jan. 1, Feb. 2018, pp. 1-9, [Retrieved on Apr. 29, 2020] Retrieved from URL: https://d…
[cited by applicant]
Anonymous: “Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma (MajesTEC-1),” National Institutes of Health, U.S. National Librar…
[cited by applicant]
Anonymous: “SinoBiological Inc—Antibody-Catalogue,” 2016, 150 Pages, Retrieved from URL: https://cdnl.sinobiological.com/reagent/catalogue/antibody-catalogue-EN.pdf.
[cited by applicant]
Anonymous (TeneoBio, Inc.): “A Study of TNB-383B in Subjects with Relapsed or Refractory Multiple Myeloma,” U.S National Library of Medicine, May 1, 2019, 8 Pages, Retrieved from URL: https://clinicaltrials.gov/ct2/show…
[cited by applicant]
“Anti-BCMA (Human) (Vicky-1) (OAED00318),” Vicky-1 Datasheet , Aviva Systems Biology, cited on Feb. 24, 2023, in the EP Opposition for EP2780375, 2 Pages.
[cited by applicant]
Armitage J.O., “A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma,” Blood, Jun. 1, 1997, vol. 89, No. 11, pp. 3909-3918.
[cited by applicant]
Armour K.L., et al., “Recombinant Human IgG Molecules Lacking Fcγ Receptor I Binding and Monocyte Triggering Activities,” European Journal of Immunology, 1999, vol. 29, No. 8, pp. 2613-2624.
[cited by applicant]
Arnett K.L., et al., “Crystal Structure of a Human CD3-ε/δ Dimer in Complex with a UCHT1 Single-chain Antibody Fragment,” Proceedings of the National Academy of Sciences, U.S.A., Nov. 16, 2004, vol. 101, No. 46, pp. 162…
[cited by applicant]
Baas T., “Superhuman Mice,” Science-Business Exchange, 2014, vol. 7, No. 17, pp. 1-2, Published Online May 1, 2014, DOI:10.1038/scibx.2014.479, ISSN 1945-3477, XP055476407.
[cited by applicant]
Baeuerle P.A., et al., “Bispecific T-Cell Engaging Antibodies for Cancer Therapy,” Cancer Research, Jun. 15, 2009, vol. 69, No. 12, pp. 4941-4944.
[cited by applicant]
Baeuerle P.A., et al., “BiTE: A New Class of Antibodies that Recruit T-cells,” Drugs of the Future, 2008, vol. 33, No. 2, pp. 137-147.
[cited by applicant]
Baeuerle P.A., et al., “BiTE: Teaching Antibodies to Engage T-cells for Cancer Therapy,” Current Opinion in Molecular Therapeutics, 2009, vol. 11, No. 1, pp. 22-30, 9 Pages.
[cited by applicant]
Banihashemi S.R., et al., “Development of Specific Nanobodies (VHH) for CD19 Immuno-Targeting of Human B-lymphocytes,” Iranian Journal of Basic Medical Sciences, 2018, vol. 21, No. 5, pp. 455-464, 10 Pages.
[cited by applicant]
Bargou R., et al., “Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody,” Science, Aug. 15, 2008, vol. 321, pp. 974-977.
[cited by applicant]
“BCMA Antibody [Vicky-1],” Vicky-1 Datasheet, GeneTex, Cat. No. GTX17323, cited on Feb. 24, 2023, in the EP Opposition for EP2780375, 1 Page.
[cited by applicant]
“BCMA Monoclonal Antibody (Vicky-1),” Invitrogen, Datasheet, Lot No. VD2967484, cited on Feb. 24, 2023 in the EP Opposition for EP2780375, 1 Page.
[cited by applicant]
“BCMA Monoclonal Antibody (Vicky-1),” Vicky-1 Datasheet, Invitrogen, cited on Feb. 24, 2023, in the EP Opposition for EP2780375, 1 Page.
[cited by applicant]
“BCMA/TNFRSF17 Antibody (Vicky-1)—BSA Free,” Vicky-1 Datasheet, Novus Biologicals, cited on Feb. 24, 2023 in the EP Opposition for EP2780375, 3 Pages.
[cited by applicant]
Beckman, et al., “Antibody Constructs in Cancer Therapy: Protein Engineering Strategies to Improve Exposure in Solid Tumors,” Cancer, 2007, vol. 109, No. 2, pp. 170-179.
[cited by applicant]
Bellucci R., et al., “Complete Response to Donor Lymphocyte Infusion in Multiple Myeloma is Associated with Antibody Responses to Highly Expressed Antigens,” Blood, Jan. 15, 2004, vol. 103, No. 2, pp. 656-663.
[cited by applicant]
Bellucci R., et al., “Complete Response to Donor Lymphocyte Infusion in Patients with Multiple Myeloma is Associated with Antibody Response to BCMA, a Plasma Cell Membrane Receptor,” Journal of the American Society of H…
[cited by applicant]
Bellucci R., et al., “Graft-versus-tumor Response in Patients with Multiple Myeloma is Associated with Antibody Response to BCMA, a Plasma-Cell Membrane Receptor,” Blood, May 15, 2005, vol. 105, No. 10, pp. 3945-3950.
[cited by applicant]
Biotechne: “Human BCMA/TNFRSF17 Antibody,” MAB193 Data Sheet, R&D Systems, Last Revised Feb. 7, 2018, 1 Page.
[cited by applicant]
Bluemel C., et al., “Epitope Distance to the Target Cell Membrane and Antigen Size Determine the Potency of T Cell-mediated Lysis by BiTE Antibodies Specific for a Large Melanoma Surface Antigen,” Cancer Immunology, Imm…
[cited by applicant]
Bodmer J-L., et al., “Review—The Molecular Architecture of the TNF Superfamily,” Trends in Biochemical Sciences, Jan. 2002, vol. 27, No. 1, pp. 19-26.
[cited by applicant]
Boesch A.W., et al., “Highly Parallel Characterization of IgG Fc Binding Interactions,” mAbs, Publication data: Landes Bioscience, US, Jul.-Aug. 2014, vol. 6, No. 4, pp. 915-927, 14 Pages.
[cited by applicant]
Borchmann P., et al., “Phase 1 Trial of the Novel Bispecific Molecule H22xKi-4 in Patients with Refractory Hodgkin Lymphoma,” Blood, Nov. 1, 2002, vol. 100, No. 9, pp. 3101-3107.
[cited by applicant]
Bossen C., et al., “BAFF, April and their Receptors: Structure, Function and Signaling,” Seminars in Immunology, 2006, vol. 18, No. 5, pp. 263-275.
[cited by applicant]
Bostrom, et al., “Improving Antibody Binding Affinity and Specificity for Therapeutic Development,” Methods in Molecular Biology, 2009, vol. 525, pp. 353-376.
[cited by applicant]
Brudno J.N., et al., “T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma,” Journal of Clinical Oncology, Aug.…
[cited by applicant]
Bruggemann M., et al., “Heavy-Chain-Only Antibody Expression and B-Cell Development in the Mouse,” Critical Reviews in Immunology, 2006, vol. 26, No. 5, pp. 377-390.
[cited by applicant]
Bruggemann M., et al., “Human Antibody Production in Transgenic Animals,” Archivum Immunologiae et Therapiae Experimentalis, Birkahaeser Verlag AG, 2015, vol. 63, No. 2, pp. 101-108, Published online on Dec. 3, 2014.
[cited by applicant]
Buelow B., et al., “Development of a Fully Human T Cell Engaging Bispecific Antibody for the Treatment of Multiple Myeloma,” Tenebio, Jun. 1, 2017, vol. 35 Supplement, No. 15, 8017 (Poster), 1 Page, DOI: 10.1200/JCO.201…
[cited by applicant]
Buelow B., et al., “Development of a Fully Human T-cell Engaging Bispecific Antibody for the Treatment of Multiple Myeloma,” Journal of Clinical Oncology, Meeting Info: 2018 ASCO-SITC Clinical Immuno-Oncology Symposium,…
[cited by applicant]
Buelow B., et al., “Effect of Modulation of Cd3 Binding in a Psmaxcd3 T-cell Engaging Bispecific Antibody on Maintenance of Efficient Tumor Cell Kill Cytokine Release,” Journal of Clinical Oncology, 2020, vol. 38, No. 1…
[cited by applicant]
Buelow B., et al., “Evaluation of Monovalent Versus Biparatopic CD3xPSMA Bispecific Antibodies for Tcell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release,” Journal of Clinical Oncology, Meeting Inf…
[cited by applicant]
Buelow B., et al., “Pre-Clinical Development of TNB-383B, a Fully Human T-cell Engaging Bispecific Antibody Targeting BCMA for the Treatment of Multiple Myeloma,” Journal of Clinical Oncology, May 20, 2018, vol. 36, No.…
[cited by applicant]
Buelow B., et al., “TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma,” Blood, …
[cited by applicant]
Buelow B., et al., “TNB585.001 : A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-585, a Bispecific T-Cell Engager Targeting PSMA in Subjects with Metastatic Castrate Resistant Prostate Can…
[cited by applicant]
Business Wire: “OMT Therapeutics Announces UniRatTM Alliance with Caltech,” May 15, 2015, 1 Page, Retrieved from URL: http://www.businesswire.com/news/home/20150514006523/en/OMT-Therapeutics-Announces-UniRat(TM)-Allianc…
[cited by applicant]
Canfield S.M., et al., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region,” Journal of Experimental Medicine…
[cited by applicant]
Caraccio C., et al., “Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials and Future Directions,” Frontiers in Immunology, Published on Apr. 24, 2020, vol. 11, Article No. 501, pp. 1-…
[cited by applicant]
Carpenter R.O., et al., “B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma,” Clinical Cancer Research, the American Association for Cancer Research, US, Apr. 15, 2013, vol. …
[cited by applicant]
CD3 Ortholog Alignment, Cited on Apr. 17, 2023 in the EP Opposition for EP2780375, 1 Page.
[cited by applicant]
Chames P., et al., “Bispecific Antibodies for Cancer Therapy,” Current Opinion in Drug Discovery & Development, 2009, vol. 12, No. 2, pp. 276-283.
[cited by applicant]